(Reuters) -Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.
The data comes months after Pfizer said it will stop global development and sale of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
A weekly injection, Hympavzi, is approved for patients with hemophilia A without factor VIII antibodies or inhibitors, or hemophilia B without factor IX inhibitors.
People with hemophilia have a defect in a gene that regulates the production of proteins called clotting factors, causing spontaneous and severe bleeding following injuries or surgery.
Pfizer said patients with inhibitors require less burdensome treatments.
The hemophilia market has been dominated by factor replacement therapies for decades.
The company said around 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue factor replacement therapies as they develop antibodies and the therapies fail to prevent or stop bleeding episodes.
(Reporting by Puyaan Singh in Bengaluru; Editing by Arun Koyyur)
Comments